Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362601872> ?p ?o ?g. }
- W4362601872 endingPage "605" @default.
- W4362601872 startingPage "587" @default.
- W4362601872 abstract "Innate or acquired resistance to small molecule BRAF or MEK1/2 inhibitors (BRAFi or MEKi) typically arises through mechanisms that sustain or reinstate ERK1/2 activation. This has led to the development of a range of ERK1/2 inhibitors (ERKi) that either inhibit kinase catalytic activity (catERKi) or additionally prevent the activating pT-E-pY dual phosphorylation of ERK1/2 by MEK1/2 (dual-mechanism or dmERKi). Here, we show that eight different ERKi (both catERKi or dmERKi) drive the turnover of ERK2, the most abundant ERK isoform, with little or no effect on ERK1. Thermal stability assays show that ERKi do not destabilise ERK2 (or ERK1) in vitro, suggesting that ERK2 turnover is a cellular consequence of ERKi binding. ERK2 turnover is not observed upon treatment with MEKi alone, suggesting it is ERKi binding to ERK2 that drives ERK2 turnover. However, MEKi pre-treatment, which blocks ERK2 pT-E-pY phosphorylation and dissociation from MEK1/2, prevents ERK2 turnover. ERKi treatment of cells drives the poly-ubiquitylation and proteasome-dependent turnover of ERK2 and pharmacological or genetic inhibition of Cullin-RING E3 ligases prevents this. Our results suggest that ERKi, including current clinical candidates, act as 'kinase degraders', driving the proteasome-dependent turnover of their major target, ERK2. This may be relevant to the suggestion of kinase-independent effects of ERK1/2 and the therapeutic use of ERKi." @default.
- W4362601872 created "2023-04-06" @default.
- W4362601872 creator A5012008199 @default.
- W4362601872 creator A5017388215 @default.
- W4362601872 creator A5025815250 @default.
- W4362601872 creator A5039474581 @default.
- W4362601872 creator A5056826438 @default.
- W4362601872 creator A5062115921 @default.
- W4362601872 creator A5080697552 @default.
- W4362601872 date "2023-05-04" @default.
- W4362601872 modified "2023-10-06" @default.
- W4362601872 title "ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1" @default.
- W4362601872 cites W1743462958 @default.
- W4362601872 cites W1848470479 @default.
- W4362601872 cites W1983028052 @default.
- W4362601872 cites W1983833034 @default.
- W4362601872 cites W1985821753 @default.
- W4362601872 cites W1986753065 @default.
- W4362601872 cites W1988031203 @default.
- W4362601872 cites W2001233441 @default.
- W4362601872 cites W2004774286 @default.
- W4362601872 cites W2008123661 @default.
- W4362601872 cites W2010022150 @default.
- W4362601872 cites W2017888183 @default.
- W4362601872 cites W2031885286 @default.
- W4362601872 cites W2034057717 @default.
- W4362601872 cites W2037519578 @default.
- W4362601872 cites W2040798958 @default.
- W4362601872 cites W2050206485 @default.
- W4362601872 cites W2054292493 @default.
- W4362601872 cites W2054946171 @default.
- W4362601872 cites W2061909885 @default.
- W4362601872 cites W2076194625 @default.
- W4362601872 cites W2083076387 @default.
- W4362601872 cites W2087609448 @default.
- W4362601872 cites W2097411278 @default.
- W4362601872 cites W2098513996 @default.
- W4362601872 cites W2102628825 @default.
- W4362601872 cites W2103588346 @default.
- W4362601872 cites W2107495112 @default.
- W4362601872 cites W2107549899 @default.
- W4362601872 cites W2109261059 @default.
- W4362601872 cites W2140219059 @default.
- W4362601872 cites W2165160051 @default.
- W4362601872 cites W2168822202 @default.
- W4362601872 cites W2170760765 @default.
- W4362601872 cites W2239096611 @default.
- W4362601872 cites W2410865989 @default.
- W4362601872 cites W2486223135 @default.
- W4362601872 cites W2559947248 @default.
- W4362601872 cites W2593126736 @default.
- W4362601872 cites W2610041238 @default.
- W4362601872 cites W2769642926 @default.
- W4362601872 cites W2775590543 @default.
- W4362601872 cites W2789608969 @default.
- W4362601872 cites W2892857541 @default.
- W4362601872 cites W2943264785 @default.
- W4362601872 cites W2974568688 @default.
- W4362601872 cites W2989877714 @default.
- W4362601872 cites W3010907970 @default.
- W4362601872 cites W3012485400 @default.
- W4362601872 cites W3032975128 @default.
- W4362601872 cites W3039594397 @default.
- W4362601872 cites W3094801273 @default.
- W4362601872 cites W3123642801 @default.
- W4362601872 cites W3186136926 @default.
- W4362601872 cites W4205379795 @default.
- W4362601872 cites W4285023155 @default.
- W4362601872 cites W4304014436 @default.
- W4362601872 doi "https://doi.org/10.1042/bcj20220598" @default.
- W4362601872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37018014" @default.
- W4362601872 hasPublicationYear "2023" @default.
- W4362601872 type Work @default.
- W4362601872 citedByCount "1" @default.
- W4362601872 crossrefType "journal-article" @default.
- W4362601872 hasAuthorship W4362601872A5012008199 @default.
- W4362601872 hasAuthorship W4362601872A5017388215 @default.
- W4362601872 hasAuthorship W4362601872A5025815250 @default.
- W4362601872 hasAuthorship W4362601872A5039474581 @default.
- W4362601872 hasAuthorship W4362601872A5056826438 @default.
- W4362601872 hasAuthorship W4362601872A5062115921 @default.
- W4362601872 hasAuthorship W4362601872A5080697552 @default.
- W4362601872 hasBestOaLocation W43626018721 @default.
- W4362601872 hasConcept C104317684 @default.
- W4362601872 hasConcept C11960822 @default.
- W4362601872 hasConcept C184235292 @default.
- W4362601872 hasConcept C185592680 @default.
- W4362601872 hasConcept C195580219 @default.
- W4362601872 hasConcept C202751555 @default.
- W4362601872 hasConcept C25602115 @default.
- W4362601872 hasConcept C27740335 @default.
- W4362601872 hasConcept C3675279 @default.
- W4362601872 hasConcept C53345823 @default.
- W4362601872 hasConcept C55493867 @default.
- W4362601872 hasConcept C57074206 @default.
- W4362601872 hasConcept C86803240 @default.
- W4362601872 hasConcept C95444343 @default.
- W4362601872 hasConcept C97029542 @default.